Akari CEO abrupt­ly re­signs as a spe­cial com­mit­tee moves a PhII pa­tient suc­cess in­to the fail col­umn

Akari Ther­a­peu­tics CEO Gur Rosh­walb is out.

The biotech re­port­ed af­ter the mar­ket closed on Tues­day that Rosh­walb had re­signed — ef­fec­tive im­me­di­ate­ly — af­ter the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.